| Literature DB >> 31213794 |
Xinwei Huang1,2, Xi Mu3, Li Deng4, Aili Fu5, Endong Pu6, Tao Tang2, Xiangyang Kong2.
Abstract
COPD, characterized by long-term poorly irreversible airway limitation and persistent respiratory symptoms, has resulted in enormous challenges to human health worldwide, with increasing rates of prevalence, death, and disability. Although its origin was thought to be in the interactions of genetic with environmental factors, the effects of environmental factors on the disease during different life stages remain little known. Without clear mechanisms and radical cure for it, early screening and prevention of COPD seem to be important. In this review, we will discuss the etiologic origins for poor lung function and COPD caused by specific adverse effects during corresponding life stages, as well as try to find new insights and potential prevention strategies for this disease.Entities:
Keywords: COPD; air pollution; chronic obstructive pulmonary disease; cigarette smoking; early origins; risk factors
Mesh:
Substances:
Year: 2019 PMID: 31213794 PMCID: PMC6549659 DOI: 10.2147/COPD.S203215
Source DB: PubMed Journal: Int J Chron Obstruct Pulmon Dis ISSN: 1176-9106
Global all-age attributable deaths and DALYs, and percentage change of age-standardized death rates and DALY rates caused of COPD by environment exposure between 2007 and 2017
| Exposure risk | 2007 deaths (million) | 2017 deaths (million) | Change in age-standardized | 2007 DALYs | 2017 DALYs | Change in age-standardized |
|---|---|---|---|---|---|---|
| Active smoking | 1.13 | 1.23 | –19.1% | 26.10 | 28.20 | –18.4% |
| Ambient particulate matter pollution | 0.519 | 0.633 | –10·5% | 12.80 | 15.70 | –6.0% |
| Occupational particulate matter, gases, and fumes | 0.425 | 0.481 | –16.1% | 10.40 | 11.90 | –12.7% |
| Ambient ozone pollution | 0.392 | 0.472 | –11.6% | 6.33 | 7.37 | –12.2% |
| Household air pollution | 0.421 | 0.362 | –36.3% | 10.800 | 9.37 | –33.5% |
| Secondhand smoke | 0.244 | 0.266 | –20.0% | 6.23 | 6.91 | –15.3% |
| Lead exposure | 0.009 | 0.011 | –3.3% | 0.286 | 0.327 | –11.0% |
Notes: This data comes from part ofthe article Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–1994.6
Figure 1The proportion of all-age deaths and DALYs for COPD attributed to active cigarette smoking, ambient particulate matter pollution, occupational particulate matter/gases/fumes, ambient ozone pollution, household air pollution from solid fuel, and secondhand smoke in 2007 and 2017.
Notes: This data comes from part of the article Stanaway JD, Afshin A, Gakidou E, et al. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1923–1994.6 R 3.5.2 version was used to plot.
Abbreviation: DALYs, disability-adjusted life-years.
Genes involved in COPD
| Gene | Chromosome | Trait related to COPD diagnosis | Other trait | References |
|---|---|---|---|---|
| 20p13 | COPD risk, FEV1 and FEV1/FVC, | Lung development, asthma, and bronchial hyperresponsiveness, | ||
| 12p12.1 | COPD risk | Lung development and/or repair processes | ||
| 2q35 | COPD risk, FEV1, and FVC | TEW, cell migration, cartilage development | ||
| 2q36.1 | COPD risk, FEV1, and FVC | Lung development | ||
| 14q13.3 | COPD risk, lung function | Lung development | ||
| 1q41 | COPD risk, FEV1/FVC | Lung development, airway remodeling, and the immune system | ||
| 4q31.21 | COPD risk, FEV1, and FVC | TEW, lung development | ||
| 9q22.32 | COPD risk, FEV1/FVC, FVC | Lung development | ||
| 22q13.31 | COPD risk | Fetal lung development | ||
| 3p24.2 | COPD risk, FEV1/FVC | Lung development | ||
| 11q22.2 | COPD risk | Lung development | ||
| 16q12.2 | COPD risk | Lung development | ||
| 11q22.2 | COPD risk | Lung development | ||
| 11q22.2 | COPD risk | Lung development, lung injury-repair response | ||
| 20q13.12 | COPD risk | Lung development | ||
| 11q22.2 | COPD risk, FVC, and FEV1/FVC | Lung development | ||
| 14q11.2 | COPD risk | Lung development, lung injury-repair response | ||
| 10q26.2 | COPD risk | Lung development | ||
| Xp11.3 | COPD risk | Lung development | ||
| 17q25.3 | COPD risk | Lung development | ||
| 22q12.3 | COPD risk | Lung development | ||
| 19p13.3 | COPD risk | Lung development, lung injury-repair response | ||
| 13q14.2 | COPD risk | Nicotine addiction | ||
| 19q13.2 | COPD risk, FEV1/FVC, and FEV1 | Nicotine addiction | ||
| 15q25.1/20q13.33/15q25.1/15q13.3 | COPD risk, FEV1/FVC, and FEV1 | Nicotine addiction | ||
| 15q25.1 | COPD risk | Nicotine addiction | ||
| 6p21.33 | COPD risk | |||
| 6q27 | FEV1/FVC | |||
| 12q23.1 | FEV1/FVC | |||
| 21q22.11 | FEV1/FVC | |||
| 6q24.2 | FEV1/FVC | |||
| 5q33.2 | FEV1/FVC | |||
| 17p12 | FEV1 | |||
| 1p36.13 | FEV1/FVC | |||
| 2q37.3 | FEV1/FVC | |||
| 3q26.2 | FEV1 | |||
| 5q15 | FEV1/FVC | |||
| 6q21 | FEV1/FVC | |||
| 6p21.33 | FEV1/FVC | |||
| 6p22.1 | FEV1 | |||
| 10p14-p13 | FEV1/FVC, and FEV1 | |||
| LRMDA (leucine rich melanocyte differentiation associated) | 10q22.2-q22.3 | FEV1 | ||
| 12q13.3 | FEV1/FVC | |||
| 12q23.1 | FEV1/FVC | |||
| 16q21 | FEV1/FVC | |||
| 16q23.1 | FEV1/FVC | |||
| 21q22.11 | FEV1/FVC | |||
| 6p21.32 | COPD risk, and FEV1/FVC | |||
| 4q22.1 | COPD risk, FEV1, and FVC | |||
| 14q32.13 | COPD risk, emphysema risk, FEV1/FVC, and FEV1 | |||
| 12q24.33 | Airflow limitation | |||
| 5p13.3 | COPD risk | |||
| 17p12 | COPD risk | |||
| 2p16.1 | FVC | |||
| 6p24.3 | FVC | |||
| 11p11.2 | FVC | |||
| 11p11.2 | FVC | |||
| 16q23.1-q23.2 | FVC | |||
| 17q24.3 | FVC | |||
| 4q24 | FVC | |||
| 5q32 | COPD risk, FEV1, and FEV1/FVC | Airway responsiveness | ||
| 11q12.3 | COPD risk, lung function | |||
| 1q42.12 | COPD risk | |||
| 15q24.1 | COPD risk | |||
| 22q11.23 | COPD risk |
Abbreviation: TEW, transient early wheeze.
The different risk factors during varied life periods of the lung
| The risk factors | The life periods of the lung | |
|---|---|---|
| 1. Genetic susceptibility factors | ①Family history of COPD, asthma, and emphysema and airway disease; | A: Before the pregnancy |
| 2.1 Antenatal or postnatal environmental risk factors | ①Maternal amniotic fluid | B: The growth and development of the lung: from the foregut at 4 weeks of gestation to 15–25 years of age |
| ②Preterm birth and birth weight gain | ||
| ③Maternal cigarette smoking | (1) Embryonic stage: 4–7 weeks of gestation | |
| ④Maternal air pollution exposure | ||
| ⑤Delivery patterns | (2) Pseudoglandular stage: 7–17 weeks of gestation | |
| ⑥Maternal obesity | ||
| ⑦Maternal diet and drug use | (3) Canalicular stage: 16–25 weeks of gestation | |
| 2.2 Early postnatal environmental risk factors | ①Childhood air pollution exposure | |
| ②Childhood asthma | (4) Saccular stage: 24–38 weeks of gestation | |
| ③Childhood respiratory infection | ||
| ④Childhood cigarette smoking exposure | (5) Alveolar stage: before birth to childhood and adolescence | |
| ⑤Childhood obesity/ | ||
| 3. Adulthood environmental risk factors | ①Adulthood cigarette smoking | C: The aging periods of the lung: 25 year of age to COPD or death occurrence |
Figure 2The origins for chronic pulmonary disease resulting from genetic and environmental factors.
Figure 3The plausible trajectories to lung function by varied risk factors in different life stages of the lung.